Shadow over breast cancer trial
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.WOMEN taking part in a controversial breast cancer drugs trial may be given a hormone supplement to reduce their risk of developing womb cancer, it emerged yesterday, writes Celia Hall.
Fifteen thousand healthy women at high risk of developing breast cancer are being asked to volunteer for the trial to see if the proven breast cancer drug tamoxifen, can prevent high-risk women from developing the disease.
But tamoxifen has been linked to an increased risk of cancer of the endometrium, the lining of the womb, and tomorrow a report in the Lancet will provide more evidence of that risk.
Dr Rajendra Kedar and colleagues from Kings College and the Royal Marsden hospitals, London, found that 39 per cent of women in the pilot tamoxifen prevention trial developed abnormal changes in the endometrium compared to 10 per cent of those taking a placebo.
None developed endometrial cancer but the abnormal changes can be an early warning sign.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments